Predict your next investment

Private Equity
yfc.cn

See what CB Insights has to offer

Investments

166

Portfolio Exits

30

Funds

6

About Yunfeng Capital

Yunfeng Capital is a private equity firm in China.

Yunfeng Capital Headquarter Location

Room 3501, 35th floor, K. Wah Centre, No. 1010 Middle Huaihai Rd.

Shanghai, Shanghai,

China

+8621-31270909

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Yunfeng Capital

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Yunfeng Capital in 4 CB Insights research briefs, most recently on Nov 10, 2021.

Latest Yunfeng Capital News

Chinese Genomics Startup Axbio Bags USD100 Million in Fundraiser With AstraZeneca an Investor

Jun 20, 2022

(Yicai Global) June 20 -- Chinese gene sequencing company Axbio has secured USD100 million in its latest financing round in which a medical industry fund run by UK pharmaceutical giant AstraZeneca and Chinese private equity firm CICC Capital took part. The medical fund joint venture together with Shanghai-based Yunfeng Capital led the B-series, venture capital news website Lieyunwang reported today. Other participants included Singaporean health-dedicated investment firm C-Bridge Capital. The new funding will allow Shenzhen-based Axbio to rapidly advance the development and commercialization of its new-generation sequencer in the fast-growing genomics market, a representative from C-Bridge Capital told Yicai Global. The firm’s first manufacturing facility in Wuxi, eastern Jiangsu province is due be completed by the end of the year, the person added. Axbio’s nanopore-based low-cost single-molecule sequencing platform is extremely important for the precision medicine market, said Marco Ma, managing director of a C-Bridge Capital subsidiary, CBC Venture. It enables fast cancer diagnostics, rapid pathogen detection and drug development. This is Axbio’s second fundraising round in nine months. In October last year, the company raised tens of millions of dollars in Series A+ financing led by several venture capital firms including Shanghai-based 5Y Capital. Editor: Kim Taylor

Yunfeng Capital Investments

166 Investments

Yunfeng Capital has made 166 investments. Their latest investment was in Axbio as part of their Series B on June 6, 2022.

CBI Logo

Yunfeng Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/20/2022

Series B

Axbio

$100M

Yes

2

6/14/2022

Unattributed VC

Robosense

Yes

2

2/17/2022

Series C - II

Ruili

Yes

1

11/29/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

11/22/2021

Series B - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/20/2022

6/14/2022

2/17/2022

11/29/2021

11/22/2021

Round

Series B

Unattributed VC

Series C - II

Series B

Series B - II

Company

Axbio

Robosense

Ruili

Subscribe to see more

Subscribe to see more

Amount

$100M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

2

1

10

10

Yunfeng Capital Portfolio Exits

30 Portfolio Exits

Yunfeng Capital has 30 portfolio exits. Their latest portfolio exit was GemPharmatech on April 25, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/25/2022

IPO

$99M

Public

1

3/31/2022

IPO - II

$99M

Public

1

1/7/2022

IPO

$99M

Public

1

12/14/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

12/2/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/25/2022

3/31/2022

1/7/2022

12/14/2021

12/2/2021

Exit

IPO

IPO - II

IPO

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Public

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Yunfeng Capital Acquisitions

11 Acquisitions

Yunfeng Capital acquired 11 companies. Their latest acquisition was Cellular Biomedicine Group on February 20, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

2/20/2021

Series A

$99M

$120M

Take Private

2

3/11/2019

$99M

Acquired

7

1/18/2019

$99M

Take Private

8

7/4/2018

Other

Subscribe to see more

$99M

$99M

Subscribe to see more

10

12/8/2017

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/20/2021

3/11/2019

1/18/2019

7/4/2018

12/8/2017

Investment Stage

Series A

Other

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$120M

$99M

Note

Take Private

Acquired

Take Private

Subscribe to see more

Subscribe to see more

Sources

2

7

8

10

10

Yunfeng Capital Fund History

6 Fund Histories

Yunfeng Capital has 6 funds, including Yunfeng IK Co-invest.

Closing Date

Fund

Fund Type

Status

Amount

Sources

1/16/2019

Yunfeng IK Co-invest

$50M

3

8/3/2018

Yunfeng Fund III

Subscribe to see more

Subscribe to see more

$99M

10

5/28/2014

Yunfeng Fund II

Subscribe to see more

Subscribe to see more

$99M

10

12/31/2010

Yunfeng Fund

Subscribe to see more

Subscribe to see more

$99M

10

Yunfeng Cloud Computing Fund

Subscribe to see more

Subscribe to see more

10

Closing Date

1/16/2019

8/3/2018

5/28/2014

12/31/2010

Fund

Yunfeng IK Co-invest

Yunfeng Fund III

Yunfeng Fund II

Yunfeng Fund

Yunfeng Cloud Computing Fund

Fund Type

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$50M

$99M

$99M

$99M

Sources

3

10

10

10

10

Yunfeng Capital Team

10 Team Members

Yunfeng Capital has 10 team members, including current Founding Partner, Jack Yun Y Ma.

Name

Work History

Title

Status

David Yu

Founder

Current

Jack Yun Y Ma

Founding Partner

Current

Yuzhu Shi

Founding Partner

Current

Yusuo Wang

Founding Partner

Current

Shiyao Guo

Managing Director

Current

Name

David Yu

Jack Yun Y Ma

Yuzhu Shi

Yusuo Wang

Shiyao Guo

Work History

Title

Founder

Founding Partner

Founding Partner

Founding Partner

Managing Director

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.